Valuation : Nuvectra Corporation

Market Cap 16.99L 14.64L 13.86L 12.56L 23.57L 16Cr 23.69L 1.65Cr 63.31L 8.26Cr 63.81L 62.41L 26Cr P/E 2017
-1.84x
P/E 2018 -5.02x
Enterprise Value -5.35Cr -4.61Cr -4.36Cr -3.95Cr -7.42Cr -510.72Cr -7.45Cr -52Cr -20Cr -259.83Cr -20Cr -20Cr -821.04Cr EV / Sales 2017
2.58x
EV / Sales 2018 4.76x
Free-Float
96.76%
Yield 2017 *
-
Yield 2018 -
Manager TitleAgeSince
Chief Executive Officer 78 31/01/2019
Compliance Officer 51 01/01/2015
Director TitleAgeSince
Director/Board Member 67 01/03/2016
Director/Board Member 78 01/03/2016
Change 5-day change 1-year change 3-year change Capi.($)
-.--%+16.67% - - 3L
-1.36%-5.89%-23.76%-0.44% 18TCr
-0.72%-3.41%-3.26%+12.32% 12TCr
+0.19%-2.83%+6.30%+80.17% 6.14TCr
-1.92%-6.01%+7.05%+38.44% 4.94TCr
+0.81%-3.73%-4.81%-32.56% 4.84TCr
-1.75%-5.54%+8.93%-20.82% 3.13TCr
+0.43%-11.10% - - 2.85TCr
+0.58%+1.84%+36.58%-12.08% 2.44TCr
+0.49%-7.65%-13.30%+3.79% 2.16TCr
Average -0.33%-2.90%+1.72%+8.60% 5.58TCr
Weighted average by Cap. -0.69%-4.90%-6.02%+10.83%

Financials

2017 2018
Net sales 3.18Cr 2.74Cr 2.6Cr 2.35Cr 4.42Cr 304.15Cr 4.44Cr 31Cr 12Cr 154.74Cr 12Cr 12Cr 488.95Cr 4.88Cr 4.21Cr 3.98Cr 3.61Cr 6.77Cr 466.51Cr 6.81Cr 47Cr 18Cr 237.34Cr 18Cr 18Cr 749.97Cr
Net income -4.46Cr -3.84Cr -3.64Cr -3.3Cr -6.19Cr -426.09Cr -6.22Cr -43Cr -17Cr -216.77Cr -17Cr -16Cr -684.98Cr -4.81Cr -4.15Cr -3.93Cr -3.56Cr -6.68Cr -459.82Cr -6.71Cr -47Cr -18Cr -233.94Cr -18Cr -18Cr -739.22Cr
Net Debt -14.9L -12.84L -12.16L -11.02L -20.67L -14Cr -20.78L -1.44Cr -55.52L -7.24Cr -55.96L -54.73L -23Cr -5.52Cr -4.75Cr -4.5Cr -4.08Cr -7.65Cr -526.95Cr -7.69Cr -53Cr -21Cr -268.09Cr -21Cr -20Cr -847.14Cr
Logo Nuvectra Corporation
Nuvectra Corporation is a neurostimulation company that focuses on helping physicians to improve the lives of people with chronic neurological conditions. The Company's Algovita Spinal Cord Stimulation (SCS) System (Algovita) is the Company's commercial offering and is Conformite Europeene (CE) marked and the United States Food and Drug Administration (FDA) approved for the treatment of chronic pain of the trunk and/or limbs. Its technology platform also has capabilities under development to support other neurological indications, such as sacral nerve stimulation (SNS) and deep brain stimulation (DBS). In addition, its NeuroNexus Technologies, Inc. (NeuroNexus) subsidiary designs, manufactures and markets neural-interface technologies for the neuroscience clinical research market. Its Virtis is an application of the Company's neurostimulation technology platform and its first product for the SNS market. Its subsidiaries include Algostim, LLC (Algostim) and PelviStim LLC (PelviStim).
Employees
-
  1. Stock Market
  2. Stocks
  3. NVTRQ Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!